{"product_id":"imab-vrio-analysis","title":"I-Mab (IMAB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to I-Mab (IMAB)'s market position as we dissect its core capabilities through the rigorous VRIO lens. This analysis distills whether its current assets truly deliver sustainable competitive advantage by examining their Value, Rarity, Inimitability, and Organization. Dive in now to see the definitive verdict on what makes I-Mab (IMAB) uniquely powerful - or potentially vulnerable - in today's landscape.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) Clinical Profile\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at I-Mab’s Givastomig, and the early clinical signals are defintely strong, especially for a first-line metastatic gastric cancer (1L mGC) setting that desperately needs better options. The core takeaway right now is that this bispecific antibody is showing best-in-class potential based on its initial efficacy data, but the real test - and the sustained advantage - hinges on the upcoming Q1 2026 data readouts.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Delivers Best-in-Class Efficacy Signal\u003c\/h3\u003e\n\u003cp\u003eThe value proposition for Givastomig is rooted in its impressive objective response rate (ORR) when combined with standard care. In the Phase 1b dose expansion cohort, which is the focus for further development, the ORR hit \u003cstrong\u003e83%\u003c\/strong\u003e (\u003cstrong\u003e10\/12\u003c\/strong\u003e patients). That’s a huge number in this space. Even across all dose levels tested in the escalation cohort, the ORR was a solid \u003cstrong\u003e71%\u003c\/strong\u003e (\u003cstrong\u003e12\/17\u003c\/strong\u003e patients). This suggests the drug works well across a broad spectrum of patients, even those with low PD-L1 or low Claudin 18.2 expression.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the key efficacy metric:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelected Dose ORR:\u003c\/strong\u003e \u003cstrong\u003e83%\u003c\/strong\u003e (\u003cstrong\u003e10\/12\u003c\/strong\u003e)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAll Doses ORR:\u003c\/strong\u003e \u003cstrong\u003e71%\u003c\/strong\u003e (\u003cstrong\u003e12\/17\u003c\/strong\u003e)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential Market Size:\u003c\/strong\u003e 1L GEC is a roughly \u003cstrong\u003e$2B\u003c\/strong\u003e potential market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is that these are early-stage combination data, and the durability of these responses needs to be proven in a randomized setting.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Unique Mechanism in a Crowded Field\u003c\/h3\u003e\n\u003cp\u003eGivastomig is rare because of its specific molecular architecture. It’s a bispecific antibody targeting Claudin 18.2 (CLDN18.2) and conditionally activating T cells via 4-1BB agonism only when it binds to the tumor cell. This conditional activation is key; it’s designed to minimize the systemic toxicities often associated with non-conditional 4-1BB agonists.\u003c\/p\u003e\n\u003cp\u003eThe rarity comes from the combination of factors:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTargeting CLDN18.2, a validated but still emerging target.\u003c\/li\u003e\n\u003cli\u003eIncorporating a silenced Fc region.\u003c\/li\u003e\n\u003cli\u003eConditional 4-1BB agonism for safety.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eHonestly, while other CLDN18.2 assets are in development, this specific design profile is not widely replicated yet.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barrier Due to Data and Design\u003c\/h3\u003e\n\u003cp\u003eReplicating Givastomig’s success is tough for competitors. Imitability is high because it requires two things: first, the complex molecular engineering to get the conditional agonism right, and second, the positive clinical data package that shows the safety\/efficacy trade-off is favorable. It takes time and significant capital to generate data like the \u003cstrong\u003e83%\u003c\/strong\u003e ORR seen in the expansion cohort.\u003c\/p\u003e\n\u003cp\u003eThe challenge for rivals is the time lag. I-Mab is already accelerating development, planning to initiate a global randomized Phase 2 study in Q1 2026. Competitors are playing catch-up to that timeline, not just to the initial concept.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Lead Program Status and Financial Runway\u003c\/h3\u003e\n\u003cp\u003eI-Mab has clearly organized around this asset, designating Givastomig as its lead program since January 2025. This focus means resources - both capital and personnel - are being directed here, evidenced by the accelerated Phase 1b enrollment. The company also recently bolstered its financial footing to support this push.\u003c\/p\u003e\n\u003cp\u003eFrom a financial perspective, organizationally, they look set for the near term:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eValue (as of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eSource\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro-Forma Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$226.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-August 2025 offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway\u003c\/td\u003e\n\u003ctd\u003eThrough \u003cstrong\u003eQ4 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExpected funding through Phase 2 trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrdinary Shares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e187,818,796\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization is structured to deliver the crucial Q1 2026 topline data, which is when the next major inflection point arrives.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Conditional Sustained Advantage\u003c\/h3\u003e\n\u003cp\u003eBased on the current profile, Givastomig holds a \u003cstrong\u003eTemporary Competitive Advantage\u003c\/strong\u003e that is poised to become \u003cstrong\u003eSustained\u003c\/strong\u003e. The current ORR is compelling, but the advantage is only temporary until the Phase 2 data proves it can hold up against the control arm in a randomized, statistically powered study.\u003c\/p\u003e\n\u003cp\u003eThe final assessment hinges on the next steps:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCurrent Status:\u003c\/strong\u003e Temporary Advantage (due to early-stage data).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCondition for Sustained Advantage:\u003c\/strong\u003e Positive results from the global randomized Phase 2 study expected to start in Q1 2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eActionable Insight:\u003c\/strong\u003e Focus all operational efforts on ensuring the Q1 2026 data package is robust and clearly demonstrates superiority over standard-of-care nivolumab plus chemotherapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Dual-Market (China\/U.S.) Global Biotech Platform\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eDual-Market (China\/U.S.) Global Biotech Platform\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Allows I-Mab to combine efficient discovery\/clinical resources in Asia with U.S. clinical development and market access capabilities. This structure supported a pipeline including uliledlimab (worldwide rights ex-Greater China) and givastomig (lead party ex-China and South Korea).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderately rare; many pure U.S. or pure China biotechs lack this integrated, dual-market operational structure. The company was founded in 2014 with the goal of leveraging the China biologics market, opening its first U.S. outpost in 2018.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate; establishing the necessary regulatory and operational infrastructure in both major markets is costly and takes time. The complexity is evidenced by the $49.4 million in one-time outflows associated with the divestiture of China operations in H1 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; this transformation into Chapter 3.0 is a deliberate organizational shift to maximize global productivity. The divestiture of China operations was completed on April 2, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; the advantage is realized now, but sustained only if they successfully integrate the two operational centers. The strategic shift aims to reduce operational costs and reallocate capital, supported by $184.4 million in cash and investments as of September 30, 2024, providing a runway into 2027.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDivestiture Consideration (Max)\u003c\/td\u003e\n\u003ctd\u003eUp to $80 million (contingent)\u003c\/td\u003e\n\u003ctd\u003eContingent on milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina Divestiture Outflow\u003c\/td\u003e\n\u003ctd\u003e$49.4 million\u003c\/td\u003e\n\u003ctd\u003eH1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSettlement of Redemption Obligations\u003c\/td\u003e\n\u003ctd\u003eApproximately $15 million\u003c\/td\u003e\n\u003ctd\u003eMid-September 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Short-Term Investments (U.S. Focus)\u003c\/td\u003e\n\u003ctd\u003e$184.4 million\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto 2027\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e$15.7 million\u003c\/td\u003e\n\u003ctd\u003eNine months ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePipeline assets retained with ex-China rights:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUliledlimab (CD73 antibody): Worldwide rights outside Greater China.\u003c\/li\u003e\n\u003cli\u003eGivastomig (CLDN18.2 X 4-1BB bispecific): Shares worldwide rights outside China and South Korea equally with ABL Bio.\u003c\/li\u003e\n\u003cli\u003eNumber of future IND candidates with right of first negotiation ex-Greater China: Three.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Strengthened Balance Sheet and Funding Runway\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eStrengthened Balance Sheet and Funding Runway\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds from August 2025 Offering\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$61.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from August 2025 Offering\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$65 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro-forma Cash Balance (Post-Offering)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$226.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (Pre-Offering)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$165.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShort-Term Investments (Pre-Offering)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Funding Runway\u003c\/td\u003e\n\u003ctd\u003eThrough the \u003cstrong\u003efourth quarter of 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargeted Data Readout (PFS for givastomig Phase 2)\u003c\/td\u003e\n\u003ctd\u003eEnd of \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe August 2025 underwritten offering provided net proceeds of approximately \u003cstrong\u003e$61.2 million\u003c\/strong\u003e. This resulted in a pro-forma cash balance of about \u003cstrong\u003e$226.8 million\u003c\/strong\u003e as of June 30, 2025, after giving effect to the offering. The cash and cash equivalents before the offering were \u003cstrong\u003e$165.4 million\u003c\/strong\u003e, with \u003cstrong\u003e$0.2 million\u003c\/strong\u003e in short-term investments as of June 30, 2025.\u003c\/p\u003e\n\u003cp\u003eThe intended use of proceeds includes funding the ongoing clinical development of pipeline product candidates, such as the randomized Phase 2 trial of givastomig, aiming to generate clinically meaningful progression-free survival (PFS) data by the end of \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eSecuring approximately \u003cstrong\u003e$61.2 million\u003c\/strong\u003e in net proceeds to ensure a funding runway through the end of \u003cstrong\u003e2028\u003c\/strong\u003e is a significant achievement for a company at this stage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGivastomig Phase 1b combination data presented at ESMO GI 2025 showed an \u003cstrong\u003e83%\u003c\/strong\u003e Objective Response Rate (ORR) in first-line gastric cancers.\u003c\/li\u003e\n\u003cli\u003eTopline data from the planned dose expansion study of givastomig is expected in \u003cstrong\u003eQ1 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors can raise capital, but the specific timing and terms achieved in the August 2025 offering, which included participation from investors such as Everest Medicines, Janus Henderson Investors, Adage Capital Partners LP, and Exome Asset Management, are specific to I-Mab's perceived value at that time.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe management team successfully executed a capital raise to de-risk near-term operations, extending the expected operational funding through the \u003cstrong\u003efourth quarter of 2028\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses for the six months ended June 30, 2025, were \u003cstrong\u003e$4.1 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$11.3 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eAdministrative expenses for the six months ended June 30, 2025, were \u003cstrong\u003e$8.3 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$14.4 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThis cash buffer buys time to generate critical data, such as the expected topline data for givastomig in \u003cstrong\u003eQ1 2026\u003c\/strong\u003e, but the advantage erodes as the runway shortens toward the end of \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Intellectual Property Portfolio (Especially Claudin 18.2 Rights)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eIntellectual Property Portfolio (Especially Claudin 18.2 Rights)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Secures the long-term commercial exclusivity for key assets like givastomig, recently bolstered by acquiring upstream rights to the parental antibody. The CLDN18.2 parental antibody utilized in givastomig has been observed to show a higher affinity to human CLDN18.2 than other antibodies, including antibodies used in approved CLDN18.2-directed therapies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs have IP, but I-Mab is actively consolidating rights (e.g., via the July 17, 2025 Bridge Health acquisition) around its lead asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; patents are legally protected, and acquiring foundational IP rights is a difficult, one-time event. For example, a patent for Anti-claudin 18.2 and anti-4-1BB bispecific antibodies was granted on March 1, 2022.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the organization is actively investing in IP consolidation to maximize asset value for potential exits. The company paused work on the Sanofi-partnered anti-CD73 antibody uliledlimab, laying off around 27% of employees to focus resources on givastomig.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as patents remain in force. Givastomig is being jointly developed with ABL Bio, with I-Mab sharing worldwide rights equally, excluding Greater China and South Korea.\u003c\/p\u003e\n\u003cp\u003eThe strategic acquisition of Bridge Health Biotech Co., Ltd. on July 17, 2025, directly impacts the financial structure of the givastomig IP:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003cth\u003eAmount\/Term\u003c\/th\u003e\n\u003cth\u003eImpact on Givastomig\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment to Bridge Health\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition cost for upstream rights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-Contingent Payments\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.2 million\u003c\/strong\u003e through 2027\u003c\/td\u003e\n\u003ctd\u003eAdditional committed cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Future Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$3.875 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eContingent future liability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Obligations\u003c\/td\u003e\n\u003ctd\u003eEliminated\u003c\/td\u003e\n\u003ctd\u003eUnencumbering givastomig of future royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFuture Milestones (Bridge Health)\u003c\/td\u003e\n\u003ctd\u003eReduced\u003c\/td\u003e\n\u003ctd\u003eReduces future milestone payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey statistical and clinical milestones related to the IP asset, givastomig:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnrollment of the planned Phase 1b dose expansion cohorts was completed ahead of schedule.\u003c\/li\u003e\n\u003cli\u003eTopline data readout for givastomig is expected in \u003cstrong\u003eQ1 of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 1b data presented at ESMO GI 2025 showed an 83% objective response rate in one cohort.\u003c\/li\u003e\n\u003cli\u003eCash balance as of September 30, 2024, was \u003cstrong\u003e$184.4 million\u003c\/strong\u003e, expected to support operations into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInterest income for the three months ended June 30, 2025, was \u003cstrong\u003e$1.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Clinical Development \u0026amp; Translational Expertise\n\u003c\/h2\u003e\n\n\u003cp\u003eThe core capability centers on the design and execution of differentiated clinical trials, exemplified by the lead program givastomig.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Metric\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eTargeting patients with low CLDN18.2 expression not eligible for approved therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eEnrollment completed ahead of schedule in the first Phase 1b dose expansion cohort for givastomig\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eCEO experience: over \u003cstrong\u003e20 years\u003c\/strong\u003e in leading and developing clinical-stage assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eClinical development capability explicitly called the 'brain' of the value creation strategy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eNext topline data readout from the Phase 1b dose expansion study expected in \u003cstrong\u003e1H 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eClinical and Financial Data Supporting Expertise:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGivastomig Phase 1 monotherapy Objective Response Rate (ORR) in heavily pretreated CLDN18.2-positive gastric cancer patients: \u003cstrong\u003e18%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGivastomig Phase 1b combination ORR at selected doses (8 mg\/kg and 12 mg\/kg): \u003cstrong\u003e83%\u003c\/strong\u003e (\u003cstrong\u003e10\/12\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eMedian Duration of Response (DOR) for givastomig monotherapy: \u003cstrong\u003e9.4 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eActivity observed across Claudin 18.2 expression levels from \u003cstrong\u003e11%\u003c\/strong\u003e to \u003cstrong\u003e100%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 Research \u0026amp; Development Expenses: \u003cstrong\u003e$21.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFirst Quarter 2025 Research \u0026amp; Development Expenses: \u003cstrong\u003e$0.8 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$6.1 million\u003c\/strong\u003e in Q1 2024.\u003c\/li\u003e\n\u003cli\u003eCash and investments as of March 31, 2025: \u003cstrong\u003e$168.6 million\u003c\/strong\u003e, providing runway into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOrganizational Structure Highlights:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInsider ownership percentage: \u003cstrong\u003e22.10%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eConsensus Analyst Rating: Moderate Buy.\u003c\/li\u003e\n\u003cli\u003eThe $2B potential market for first-line GEC is the target for givastomig.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Asset Sourcing and Business Development Network\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eAsset Sourcing and Business Development Network\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nValue: Provides access to a pipeline of novel molecules through deep roots in Asia and a dedicated team that screens hundreds of biotech companies annually.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: High; the deep, day-to-day BD\/investment team presence on the ground in Asia for sourcing is a distinct advantage.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: High; this network is built on years of relationships and trust, not just capital.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: High; this capability underpins their in-licensing strategy and global partnership framework.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Sustained, as long as the BD team remains intact and effective.\n\u003c\/p\u003e\n\u003cp\u003e\nThe operational and financial foundation supporting the Business Development network includes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of June 30, 2025, the Company had cash and cash equivalents, and short-term investments of \u003cstrong\u003e$165.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePro-forma cash balance of approximately \u003cstrong\u003e$226.8 million\u003c\/strong\u003e as of June 30, 2025, after giving effect to the August 2025 underwritten offering.\u003c\/li\u003e\n\u003cli\u003eExpected cash runway through the \u003cstrong\u003efourth quarter of 2028\u003c\/strong\u003e based on the pro-forma cash balance.\u003c\/li\u003e\n\u003cli\u003eAs of December 31, 2023, cash and cash equivalents, and short-term investments totaled \u003cstrong\u003eRMB2.3 billion (US$321.8 million)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nKey strategic transactions indicative of the BD network's output include:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeal\/Asset Focus\u003c\/td\u003e\n\u003ctd\u003ePartner\/Counterparty\u003c\/td\u003e\n\u003ctd\u003eRetained Rights\/Consideration\u003c\/td\u003e\n\u003ctd\u003eDate\/Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDivestiture of Greater China Assets\u003c\/td\u003e\n\u003ctd\u003eI-Mab Biopharma (Hangzhou) Co., Ltd.\u003c\/td\u003e\n\u003ctd\u003eRetained ex-China rights for givastomig, uliledlimab, and TJ-L14B. Potential aggregate consideration up to \u003cstrong\u003eUS$80 million\u003c\/strong\u003e in milestones.\u003c\/td\u003e\n\u003ctd\u003eCompleted April 2, 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFelzartamab (TJ202\/MOR202) \u0026amp; TJ210 (MOR210)\u003c\/td\u003e\n\u003ctd\u003eMorphoSys AG\u003c\/td\u003e\n\u003ctd\u003eI-Mab retains exclusive rights for felzartamab in Greater China.\u003c\/td\u003e\n\u003ctd\u003eAnnounced June 15, 2022.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGivastomig (CLDN18.2 X 4-1BB bispecific)\u003c\/td\u003e\n\u003ctd\u003eBristol Myers Squibb\u003c\/td\u003e\n\u003ctd\u003eClinical collaboration and supply agreement.\u003c\/td\u003e\n\u003ctd\u003eAdvanced in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe current global pipeline, a direct result of sourcing and development strategy, consists of:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eThree\u003c\/strong\u003e clinical stage drug candidates as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eLead programs include givastomig (CLDN18.2 x 4-1BB bispecific), uliledlimab (CD73 mAb), and ragistomig (PD-L1 x 4-1BB bispecific).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Operational Cost Management and Efficiency\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrated ability to streamline operations, cutting Research and Development expenses by \u003cstrong\u003e63.9%\u003c\/strong\u003e (from \u003cstrong\u003e\\$11.3 million\u003c\/strong\u003e for 6M 2024 to \u003cstrong\u003e\\$4.1 million\u003c\/strong\u003e for 6M 2025) and administrative costs by \u003cstrong\u003e42.2%\u003c\/strong\u003e over the first half of 2025 (from \u003cstrong\u003e\\$14.4 million\u003c\/strong\u003e in 6M 2024 to \u003cstrong\u003e\\$8.3 million\u003c\/strong\u003e in 6M 2025).\u003c\/p\u003e\n\u003cp\u003eThe operational efficiency is quantified by the following financial metrics for the six months ended June 30:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e6M 2024 Amount\u003c\/th\u003e\n\u003cth\u003e6M 2025 Amount\u003c\/th\u003e\n\u003cth\u003ePercentage Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$11.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-63.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdministrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$14.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$8.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-42.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Continuing Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$50.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$7.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-84.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe R\u0026amp;D expense reduction was primarily due to reimbursements recognized under an existing collaboration agreement and lower contract research organization costs due to streamlined clinical pipeline activities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; cost-cutting is common, but achieving these specific, large percentage reductions through pipeline streamlining and corporate restructuring is noteworthy. The R\u0026amp;D decrease included a \u003cstrong\u003e97%\u003c\/strong\u003e drop in Direct Clinical Development Expenses, from \u003cstrong\u003e\\$5.8 million\u003c\/strong\u003e in H1 2024 to a minimal \u003cstrong\u003e\\$0.2 million\u003c\/strong\u003e in H1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a result of specific strategic decisions (divestiture of Greater China assets, headcount adjustments) that are not easily replicated by competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the organization successfully executed a leaner operating model post-divestiture. This execution resulted in lower employee benefit and compensation expenses due to lower headcount.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe organization completed the divestiture of Greater China assets and business operations.\u003c\/li\u003e\n\u003cli\u003eThe administrative expense decrease was partially attributed to a decrease in legal expenses and lower employee benefit and compensation expenses resulting from a lower headcount.\u003c\/li\u003e\n\u003cli\u003eThe organization recorded \u003cstrong\u003eno\u003c\/strong\u003e equity in loss of affiliates for the six months ended June 30, 2025, compared to \u003cstrong\u003e\\$1.0 million\u003c\/strong\u003e for the six months ended June 30, 2024, which was related to employee stock ownership plan expenses from the unconsolidated investee due to the divestiture.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; efficiency gains are often temporary as development costs naturally rise with later-stage trials, and the company anticipates increased R\u0026amp;D cash burn as the randomized Phase 2 trial for givastomig ramps up.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Global Partnership and In-Licensing Framework\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Enables the company to access external innovation, exemplified by the joint development of givastomig with ABL Bio, sharing worldwide rights outside of China\/South Korea. The value accessed through such frameworks is evidenced by potential external deal structures, such as one where the partner is eligible to receive up to £2.075 billion in research, development, regulatory, and commercialization milestone payments, including an immediate upfront payment of £38.5 million. Another comparable external agreement structure cited an upfront payment of USD $40 million and up to USD $2.562 billion in milestones.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs license in, but I-Mab’s structure for sharing rights globally is a specific, established model.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; establishing global co-development agreements requires significant legal and scientific vetting.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this framework is essential for their asset-sourcing-to-exit strategy, supported by a focused financial structure. The company reported $168.6 million in cash and investments as of March 31, 2025, providing a runway into 2027. Following an August 2025 offering, cash and investments were expected to fund operations through the fourth quarter of 2028. This organizational focus was solidified by the divestiture of China operations, which included contingent consideration of up to the RMB equivalent of $80 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as key agreements remain active and new ones are secured.\u003c\/p\u003e\n\u003cp\u003eThe framework's execution is detailed in the lead asset partnership:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership Component\u003c\/td\u003e\n\u003ctd\u003eGivastomig (ABL111) Co-Development with ABL Bio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic Rights Split\u003c\/td\u003e\n\u003ctd\u003eWorldwide rights equally shared, excluding Greater China and South Korea\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eI-Mab Role\u003c\/td\u003e\n\u003ctd\u003eLead Party\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Indication (Phase 1b)\u003c\/td\u003e\n\u003ctd\u003eMetastatic Gastric Cancers (1L setting in combination with nivolumab plus chemotherapy)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eObserved Efficacy (Dose Escalation)\u003c\/td\u003e\n\u003ctd\u003e83% Objective Response Rate (ORR) at 8 mg\/kg and 12 mg\/kg dose levels (10\/12 patients)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpstream IP Strengthening Cost (Bridge Health Acquisition)\u003c\/td\u003e\n\u003ctd\u003e$1.8 million upfront payment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpstream IP Strengthening Contingent Payments\u003c\/td\u003e\n\u003ctd\u003e$1.2 million non-contingent payments through 2027 plus up to $3.875 million in future milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey financial metrics supporting the operational capacity to maintain and execute these global frameworks include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents, and short-term investments as of June 30, 2025: $165.6 million.\u003c\/li\u003e\n\u003cli\u003eNet loss for the three months ended March 31, 2025: $(3.2) million (compared to $(16.3) million in Q1 2024).\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended March 31, 2025: $0.8 million (compared to $6.1 million in Q1 2024).\u003c\/li\u003e\n\u003cli\u003eADSs issued and outstanding as of June 30, 2025: 81,786,164.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eI-Mab (IMAB) - VRIO Analysis: Targeted Precision Immuno-Oncology Focus\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eTargeted Precision Immuno-Oncology Focus\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Focuses limited resources on high-potential precision medicine targets, specifically immuno-oncology agents, rather than broad therapeutic areas. The lead asset, givastomig (CLDN18.2 x 4-1BB bispecific antibody), is prioritized for first-line metastatic gastric cancers, a market impacting more than 250,000 people globally.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many companies have this focus, but I-Mab's specific concentration on agents like bispecific antibodies is a clear strategic choice. The development of givastomig shows activity across a range of CLDN18.2 expression levels, with responses observed in monotherapy patients with expression from 11% to 100%.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a strategic decision, but the execution around that focus (like givastomig's design) is what matters. The execution includes a global partnership with ABL Bio for givastomig, where I-Mab shares worldwide rights (excluding Greater China and South Korea) equally.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the entire pipeline and R\u0026amp;D investment is aligned with this precision oncology mandate. Total R\u0026amp;D expenditure in immunotherapy research for 2023 was $95.2 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the market focus can shift, but the current alignment drives near-term value, supported by a pro-forma cash balance of approximately $226.8 million as of June 30, 2025, extending the cash runway through Q4 2028.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Status\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGivastomig Monotherapy ORR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18% (8\/45)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpdated as of Q4 2025 presentation data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGivastomig Combination ORR (Dose Expansion)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e83% (10\/12)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt 8 mg\/kg and 12 mg\/kg doses in Phase 1b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1b Dose Escalation Cohort Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003en = 17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompleted enrollment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Short-Term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$165.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Extension\u003c\/td\u003e\n\u003ctd\u003eThrough \u003cstrong\u003eQ4 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-August 2025 offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 R\u0026amp;D Investment (Immunotherapy)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$95.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal expenditure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePipeline Assets Aligned with Precision Focus:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGivastomig (CLDN18.2 x 4-1BB bispecific antibody) - Lead Program\u003c\/li\u003e\n\u003cli\u003eRagistomig (PD-L1 x 4-1BB bispecific)\u003c\/li\u003e\n\u003cli\u003eUliledlimab (CD73 monoclonal antibody)\u003c\/li\u003e\n\u003cli\u003eTotal clinical candidates: \u003cstrong\u003e5\u003c\/strong\u003e precision medicine therapeutic candidates\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516186189973,"sku":"imab-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/imab-vrio-analysis.png?v=1740183754","url":"https:\/\/dcf-model.com\/products\/imab-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}